Immunic, Inc. — 2020 Form 10-K Summary
Business context and reporting period
For the fiscal year ended December 31, 2020, Immunic was a clinical-stage biopharmaceutical company developing oral therapies for inflammatory and autoimmune diseases. Its three clinical programs were IMU-838 (DHODH inhibitor), IMU-935 (RORγt inverse agonist) and IMU-856 (intestinal-barrier function modulator). The company had no approved products or product-sales revenue. The 10-K reports full-year results; it also provides unaudited fourth-quarter figures. Immunic AG is the accounting predecessor following the 2019 reverse acquisition.
Financial performance and liquidity
| Metric | 2020 | 2019 |
|---|---|---|
| Product-sales revenue | None | None |
| Research and development expense | $38.6 million | $22.5 million |
| General and administrative expense | $10.3 million | $14.5 million |
| Total operating expenses | $49.0 million | $37.0 million |
| Net loss | $44.0 million | $34.9 million |
| Net loss per share, basic and diluted | $2.81 | $4.52 |
| Cash used in operating activities | $46.1 million | $28.5 million |
| Cash and cash equivalents at year-end | $127.5 million | $29.4 million |
Fourth-quarter 2020 operating expenses were $14.2 million and net loss was $11.2 million. Gross margin and operating margin are not meaningful for this pre-commercial company. The 2020 net loss increased 26%; R&D expense rose 72%, while G&A expense fell 29%, mainly because 2019 included non-recurring transaction-related stock compensation.
Year-end total assets were $167.9 million, total liabilities $9.1 million, and stockholders’ equity $158.8 million. Current assets were $133.7 million versus current liabilities of $8.4 million. Financing activities provided $144.4 million in 2020, principally from equity offerings; investing activities used $0.1 million. The company reported no drawn debt at year-end. Its EIB facility allows up to €24.5 million in milestone-dependent tranches and includes interest, repayment obligations, covenants and a revenue-based payment component.
Management expected existing cash to fund operations into the second half of 2022, while the filing also states that cash was expected to fund operations beyond twelve months from issuance of the financial statements. These are estimates dependent on assumptions, clinical spending and access to additional capital. The company raised approximately $134 million net from its April, June and August 2020 offerings and ATM sales; additional ATM and shelf capacity remained available at year-end, but future equity issuance could dilute shareholders.
Material changes, outlook and key developments
- IMU-838 in RRMS: The Phase 2 EMPhASIS trial reported statistically significant reductions in MRI lesions versus placebo: 62% for 45 mg and 70% for 30 mg. An approximately 60-patient 10 mg cohort was fully enrolled, with interim data expected in late March or early April 2021. The company planned end-of-Phase 2 regulatory discussions around the end of Q1 2021 and expected a potential Phase 3 start in the second half of 2021; final design and timing remained subject to regulatory feedback.
- IMU-838 in ulcerative colitis: Phase 2b CALDOSE-1 continued enrolling. Recruitment was expected to finish in the second half of 2021, with induction-phase top-line data expected in the first half of 2022. COVID-19-related site and hospital access constraints affected enrollment.
- IMU-935 and IMU-856: Both were in Phase 1 studies. The company planned further patient or dose cohorts during 2021; unblinded safety data were expected in the second half of 2021. GBS was prioritized as a potential orphan indication for IMU-935.
- Subsequent COVID-19 update: In February 2021, the company reported descriptive clinical activity in the CALVID-1 Phase 2 trial, including improvements in recovery measures and biomarker findings. Primary and key secondary endpoints were not evaluable because serious complications were uncommon. A complete analysis of 223 randomized patients was expected in Q2 2021. These results were announced after year-end and were not a completed 2020 outcome.
- Subsequent PSC update: February 2021 top-line results came from a small investigator-sponsored study curtailed during the pandemic: 18 patients enrolled and 11 completed treatment. ALP decreased significantly in the per-protocol group, but the trend was not significant in the intent-to-treat analysis. The limited sample and attrition constrain interpretation.
Risks, contingencies and unusual items
Immunic had incurred losses every year since inception, with an accumulated deficit of $103.9 million, and expected substantial future R&D spending. Its outlook depends on uncertain clinical results, regulatory approval, patient recruitment, manufacturing and financing. COVID-19 disrupted trials and could continue to delay development. The company relies on third-party CROs and manufacturers and may need further equity, debt or collaboration financing. EIB covenants could restrict operations or accelerate repayment if breached. The EIB facility was undrawn at year-end.
Other notable items include a $2.5 million foreign-exchange gain on an intercompany loan and increased Australian R&D tax incentives contributing to higher other income. The company reported no material pending litigation. Management concluded disclosure controls and internal control over financial reporting were effective; the auditor issued an unqualified opinion and identified accruals for clinical-trial R&D costs as a critical audit matter. The filing also discloses an attempted unauthorized email-account access in July 2020; the company said it did not believe confidential or proprietary information was compromised.
Important facts for investors to verify
- Confirm the full RRMS Phase 2 dataset, 10 mg cohort findings and regulatory feedback before relying on Phase 3 plans.
- Review complete CALVID-1 results and whether any clinical benefit is supported by prespecified statistical analyses; the reported main analysis was descriptive.
- Assess the implications of the small, high-attrition PSC study and the full UC trial enrollment and readout timetable.
- Reconcile projected cash runway with operating cash burn, future trial costs, available ATM capacity and potential shareholder dilution.
- Review EIB draw conditions, repayment terms, covenants, revenue-based payments and the effects of foreign-exchange movements.